01/07/26 - General information
The Hospital del Mar Research Institute has presented its new Impact Department, a cross-cutting structure created to strengthen the centre's capacity to generate, measure, transfer and communicate the impact of research and innovation to society. Its creation responds to the evolution of the research and innovation system and to the growing importance that organisations such as CERCA, the ISCIII, AQuAS and other stakeholders in the sector place on the generation and demonstration of impact. This comes in a context in which research centres must go beyond scientific excellence and be able to demonstrate the value their activity brings to patients, the healthcare system and society.
Més informació "HMRIB launches its Impact Department to promote the social return of research"
02/07/26 - General information
The project involves the launch of IAM-CAT, an integrated registry of acute myocardial infarction that aims to improve planning and epidemiological surveillance, quality of care and research in cardiovascular health. The IAM-CAT project, led by the Hospital del Mar Research Institute (HMRIB) and Hospital del Mar, has received the Bronze Award at the National Health System (SNS) Good Practices Conference, held on 9 June. The conference aims to identify and disseminate good practices that contribute to the sustainability of the SNS through the exchange of experiences and knowledge transfer among the health services of Spain's autonomous communities.
29/06/2026 - General information
An international consortium led by the Hospital del Mar Research Institute (HMRIB) and Hospital del Mar, within the International Stroke Genetics Consortium, has identified two genetic variants that may be responsible for one of the most serious complications following aneurysmal subarachnoid haemorrhage (aSAH), a type of stroke associated with poor outcomes that predominantly affects young women. The study, published in Brain, shows that the COL6A6 and PIK3R4 genes may be linked to an increased risk of delayed cerebral ischaemia, a complication that affects approximately one in four patients diagnosed with this condition.
Més informació "Genetics behind one of the main complications following subarachnoid haemorrhage"
25/06/2026 - General information
Dr. Toni Celià-Terrassa, Principal Investigator and Head of the Cancer Cell States and Metastatic Immunity Research Group at the Hospital del Mar Research Institute (HMRIB), has been awarded one of the European Union's prestigious ERC Advanced Grants. The grant provides €2.5 million to develop a project focused on generating new therapeutic strategies for breast cancer. The project, named PLASTWIRE (Re-wiring Tumor Immune-Evasive Plasticity with mRNA Therapy), will explore over the next five years the possibility of modifying the immune-evasive cellular states of tumour cells. Tumour heterogeneity is one of the main drivers of treatment resistance and therapeutic failure.
22/06/2026 - General information
Ayahuasca is a powerful Amazonian brew known to induce profound effects, including the so-called ego dissolution-a temporary alteration in the usual sense of self or personal identity. But how does it produce these effects? An international study led by the Applied Metabolomics Research Group at the Hospital del Mar Research Institute (HMRIB) has shown that the experience arises through a complex coordination between the body, the brain, and consciousness itself. The findings have been published in Biomedicine & Pharmacotherapy. Researchers from Maastricht University in the Netherlands and Goethe University Frankfurt in Germany also participated in the study.
18/06/2026 - Press release
A study in mice by the Hospital del Mar Research Institute and the IIBB-CSIC, published in Science Advances, identifies inhibition of the PARP2 protein as a therapeutic target for treating pancreatic cancer, the third leading cause of cancer death worldwide. The study analyses the role of this protein in tumour development and protection, and describes how its elimination leads to tumour cell death and activation of the immune system. Specifically blocking this protein may be a useful strategy for treating a large number of patients with pancreatic cancer and could even be applicable to other types of tumours.
16/06/2026 - General information
Hospital del Mar Research Institute (HMRIB) once again took part in the "Visita la recerca de La Marató" initiative, promoted by the Fundació La Marató of 3Cat, opening its doors to the public to showcase the biomedical research made possible through the solidarity of thousands of donors. Four guided visits were organised during May and June-three in the morning and one in the afternoon-and were met with an excellent response from participants. The sessions provided an opportunity to learn about three projects funded by the 2021 La Marató on Mental Health and the 2022 La Marató on Cardiovascular Health, focusing on two major health challenges: suicide prevention and stroke.
15/06/26 - Institutional news
The European Network of Comprehensive Cancer Centres (EUnetCCC) has designated fourteen Comprehensive Cancer Centres (CCCs) across Spain, representing a significant step towards more coordinated, equitable, and accessible cancer care throughout Europe. In Catalonia, the EU-Designated CCCs are Hospital del Mar and the North Catalonia Comprehensive Oncology Consortium. The other designated centres are CCC Euskadi-Basque Country, Hospital Universitario Regional de Málaga, Hospital Universitario Virgen del Rocío in Seville, Hospital Reina Sofía in Córdoba, CICCAR of Cantabria and La Rioja, Complejo Asistencial Universitario de Salamanca, the Murcia Health Service, Hospital Universitari i Politècnic La Fe in Valencia, the Aragón Comprehensive Oncology Network, ASTUR-CCC in Asturias, the Comprehensive Cancer Centre of Galicia, and Hospital Universitario de Navarra.
12/06/2026 - Institutional news
The Mar Tech Transfer Academy concluded its first edition on 10 June, looking ahead to future editions. Its sixth session, featuring Jordi Martorell, CEO of Aortyx, celebrated the graduation of the projects that took part in the programme. The initiative was created to serve as a bridge between research and the market through three key pillars: sessions led by experienced professionals sharing expertise in areas such as intellectual property protection, fundraising and industrialisation; the provision of support tools to help researchers maximise the value of their projects; and expert guidance throughout the entire process. Judit Cubedo, Managing Director of Hospital del Mar Research Institute, closed the programme by presenting diplomas to the participating researchers. The session concluded with a final networking and working meeting, maintaining the collaborative spirit of the initiative.
11/06/2026 - General information
A new project investigating the mechanisms of chemotherapy resistance in T-cell acute lymphoblastic leukaemia (T-ALL) receives funding from the Deutsche José Carreras Leukämie Stiftung. The study is co-led by Dr Anna Bigas, Group Leader at the Hospital del Mar Research Institute and the Josep Carreras Leukaemia Research Institute, and Professor Christoph Plass of the German Cancer Research Center. T-cell acute lymphoblastic leukaemia (T-ALL) is an aggressive haematological malignancy that affects both children and adults. Although current treatment regimens achieve remission in a high proportion of patients, resistance to chemotherapy remains the leading cause of relapse and is associated with poor clinical outcomes. Understanding the biological mechanisms that enable certain leukaemic cells to survive treatment is therefore a major unmet medical need and essential for the development of new therapeutic strategies.
Servei de Comunicació:
Marta Calsina(ELIMINAR)
Tel:
(+34) 93 316 06 80
Doctor Aiguader, 88
08226 Barcelona
© Institut Hospital del Mar
d'Investigacions MèdiquesLegal Notice and Privacy Policy | Cookie Policy | Site Index | Accessibility | Find Us | Contact
